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Background 
Constipation is a common condition affecting 
all age groups.  It is defined as the infrequent and 
difficult passage of stool.1   
One of the most common constipation myths is 
that a person must have a daily bowel movement.  
In healthy individuals, bowel movement 
frequency varies from three times a day to three 
per week.  With infrequent bowel movements, a 
person may have difficulty in passing a stool and 
may experience straining or a feeling of 
incomplete bowel evacuation.  This may be 
accompanied by a feeling of pain.1  
Another myth about infrequent bowel 
movements is that waste materials in the stool will 
be absorbed, poison the body, and shorten one’s 
life.  This “autointoxication” concept is not 
supported with scientific evidence.2 
These common myths lead many to perceive 
they are constipated when they are not and 
contribute to widespread overuse and abuse of 
laxatives.   
 
Commentary 
Common causes of constipation include poor 
diet lacking fiber, inadequate fluid intake, and 
poor bowel habits.  Constipation can result from 
diseases or conditions such as fissures or 
hemorrhoids, hypothyroidism, irritable bowel 
syndrome, lupus, scleroderma, multiple sclerosis, 
Parkinson’s disease, spinal cord injury, tumors, 
and cancers.  Loss of body fluids through 
vomiting or diarrhea, extended travel, and 
prolonged inactivity are also causes.  Pregnancy is 
a common cause of constipation.  Medications 
with anticholinergic activity, aluminum 
containing antacids, iron supplements, calcium 
channel blockers, opioids, and others frequently 
cause constipation.   
Whenever constipation lasts for longer than 
three weeks, presents with severe painful 
symptoms, is accompanied by rectal prolapse or 
any bleeding, a physician or other healthcare 
professional should be consulted.   
Frequently, dietary or lifestyle changes will 
improve the occasional bout of constipation.  
Adequate fluid intake, a well-balanced diet with 
ample fruits and vegetables, and regular exercise 
will minimize problems.  
Those suffering from chronic constipation will 
need a prescriptive treatment plan.  This plan 
usually starts with fiber laxative supplementation, 
which is gradually increased until a goal of 20 g 
per day is reached.  The addition of a saline 
laxative, such as milk of magnesia, is the usual 
second step in treating chronic constipation.  
When these steps fail, the use of stimulant 
laxatives is recommended.3  
Recommended treatments for patients at the 
initiation of opioid therapy include stool softeners 
such as docusate in combination with a stimulant 
laxative.  Bulk-producing fiber agents are not 
recommended for use in combating opioid-
induced constipation.4  
One of the myths about constipation centers 
around the chronic use of stimulant laxatives.  
Traditional thought on these stimulants has been 
that they are for short-term use only.  Their long-
term use was believed to decrease normal colon 
function through detrimental effects on enteric 
nerve and smooth muscle.  Other myths include 
increased risk of cancer, tolerance, and addiction 
or abuse due to chronic use of stimulant 
laxatives.2   
Stimulant laxatives containing aloe, cascara 
sagrada, casanthranol, cascara bark, and their fluid 
extracts were removed from the market in 2002 
because they were not recognized by the FDA as 
safe and effective.3  Manufacturers of products 
containing these ingredients failed to provide the 
FDA with data needed for them to stay on the 
market.3 
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The myth that stimulants have detrimental 
effects on enteric nerve and smooth muscle is not 
supported by clinically documented studies.  
Rather, studies were uncontrolled and only 
observational in humans and animals.  Some 
studies involved patients who used laxatives for 
longer than ten years at 18 times the 
recommended doses.2,5  One controlled trial of 
anthraquinone laxative use in constipated women, 
using biopsy and electron microscopy with 
subsequent ultra morphometry, did not reveal any 
degenerative changes in colonic nerve tissue for 
either group.6 
An association of stimulant laxatives and 
increased risk of cancer has not been 
demonstrated.  In a metaanalysis of 14 prior 
studies of cathartic agents, it was found that 
constipation and cathartics were associated with a 
much lower odds ratio than various dietary 
components, such as fat, meat, alcohol, and low-
residue diets.7  Phenolphthalein was banned by the 
FDA because of increased cancer risk in animals.  
Yet a subsequent large case-controlled study 
disproved the association and identified that doses 
used in the animal studies excessively exceeded 
human doses.2  In 1998 the FDA requested 
carcinogenicity data on both bisacodyl and senna.  
When bisacodyl animal model study results were 
submitted to the FDA, the agency concluded that 
the drug was safe and effective when used at the 
recommended dose and did not display any tumor 
risks for humans.2    The final over-the-counter 
(OTC) laxative monograph rule, effective 
November 5, 2002, stated that data were 
submitted to the FDA regarding senna’s safety 
and efficacy as an OTC laxative, and that future 
publications would address senna’s role as an 
acceptable OTC laxative. It also stated that 
stimulant laxative ingredients like cascara or 
casanthranol be reformulated to contain senna 
instead.8 
Tolerance, the need to increase laxative dose to 
maintain the desired response, may be uncommon 
in most laxative users.2  Though not extensively 
studied in humans, a clinical study by Preston and 
Lennard-Jones did not show a loss of stimulant 
laxative effect except in patients with slow-transit 
constipation.2,9  With worsening constipation, the 
dose of a laxative may need to be increased but 
not because of reduced efficacy. 
The myth that stimulant laxatives cause 
addiction or abuse results from the belief that their 
use contributes to weight-loss.  Laxative-induced 
diarrhea for the purpose of weight loss is not a 
therapeutic goal.   
Prevention of constipation is an optimal goal 
for everyone.    Eating a well-balanced diet that 
includes grains, fresh fruits and vegetables, along 
with drinking plenty of fluids, and exercising 
regularly will help with prevention.  Knowledge 
about normal bowel movement frequency 
alleviates many fears.  
When constipation does occur, fiber laxatives 
are a first choice for treatment.  Constipation 
lasting longer than three weeks or when 
accompanied by pain or bleeding should be 
discussed with a healthcare professional.  When 
laxatives are needed for treating a medical 
condition or as part of a treatment plan for drug-
induced constipation, chronic laxative use should 





Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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